• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

IntegraMed Ranked on Fortune's 100 Fastest Growing Small Public Companies List for Third Time

Posted on: Wednesday, 11 July 2007, 15:05 CDT

IntegraMed America, Inc. (NASDAQ: INMD), the nation's largest provider of business services and products to the fertility segment of the healthcare industry, announced it has been ranked number 73 on Fortune's 100 Fastest Growing Small Public Companies List for 2007. Today's announcement marks the third time that IntegraMed has been ranked on the list.

The Fortune 100 Fastest Growing Small Public Companies List is based on percentage growth in earnings, revenue and stock performance over the past three years for companies with revenues of less than $200 million and a stock price of more than $1.00. The 2007 rankings are based on performance measures in 2004, 2005 & 2006. Banks, real estate firms and certain entertainment companies were excluded from Fortune's calculations.

Factors contributing to IntegraMed's strong operating performance included ongoing operating efficiencies provided by group purchasing of personnel benefits; new patient marketing programs delivering industry leading performance; reduced malpractice premiums for participating members achieved by ARTIC, IntegraMed's own malpractice insurance subsidiary; the addition in 2006 of six new practices to its network of fertility clinics nationwide and the continuing success of its Shared Risk™ Refund Program for in vitro fertilization procedures.

"IntegraMed continues to execute its strategy of leveraging our investments, expertise, infrastructure and people for the benefit of our patients, payors and providers," said Jay Higham, president and CEO of IntegraMed America. "Our inclusion in the Fortune list this year is a sign post that we continue to demonstrate competitive advantage and provide value and return on investment for our partners and customers. While we will continue to evaluate opportunities to further leverage our resources and competitive strengths, we all recognize that the most successful, growth-oriented centers in our network continually focus their efforts on providing superior care, attracting and retaining patients, managing their business, and planning for long-term growth."

About IntegraMed America, Inc. (www.integramed.com)

IntegraMed America, Inc. is the leading provider of business services and products to the $3 billion fertility industry. These services include financing, administration, state-of-the art clinical and financial information management systems, marketing and research. IntegraMed also distributes pharmaceutical products and offers treatment-financing programs directly to consumers, and operates the Web site http://www.integramed.com, a leading fertility portal. The IntegraMed network constitutes 30 contracted fertility centers in 97 locations across the United States, including 164 physicians and Ph.D. scientists. Network membership is limited to one practice per metropolitan area, yet one of every five procedures in the U.S. is performed in an IntegraMed practice.

Statements contained in this press release that are not based on historical fact, including statements concerning future results, performance, expectations and expansion of IntegraMed are forward-looking statements that may involve a number of risks and uncertainties. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the risks associated with IntegraMed's ability to finance future growth; the loss of significant business services contract(s); profitability at Reproductive Science Centers serviced by IntegraMed; changes in insurance coverage, government laws and regulations regarding health care or managed care contracting; and other risks, including those identified in the company's most recent Form 10-K and in other documents filed by IntegraMed with the U.S. Securities and Exchange Commission. All information in this press release is as of July 11, 2007 and IntegraMed undertakes no duty to update this information.

Source: Business Wire

More News in this Category